Results 271 to 280 of about 970,341 (351)

Dialysis for Parathyroid Tumor Crises to Combat Ventricular Arrhythmia Risk: A Report of 2 Cases. [PDF]

JCEM Case Rep
Qi QYD, Gong JY, So M, Yates CJ, Fourlanos S.   +4 more
europepmc   +1 more source

Diltiazem N‐oxide, a novel ischaemia‐activated prodrug, prevents ischaemia‐induced ventricular fibrillation without off‐target adverse effects

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Ventricular fibrillation (VF) in coronary heart disease accounts for up to 70% of sudden cardiac death. We examined whether diltiazem N‐oxide (DNO) has ischaemia‐selective antiarrhythmic activity. Experimental Approach Randomised and blinded experiments were performed in rat isolated hearts and in anaesthetised rats to ...
Louise M. Hesketh, Gabriel A. Watson, Francesca Mazzacuva, Zoe Hoare, Thomas R. Eykyn, Michael J. Curtis   +5 more
wiley   +1 more source

Successful Epicardial Ablation of Ventricular Arrhythmia From the Epicardial Side of the Interventricular Septum. [PDF]

JACC Case Rep
Chokr MO, Bruno Dos Santos Sousa Í, Linhares PV, Pinto Vandoni PM, de Biase V, Ogama MH, Tebet M, Ferreira de Souza O, Augusto de Luca F.   +8 more
europepmc   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Ventricular Arrhythmia Risk Stratification Among Patients With Cardiac Resynchronization Therapy Devices. [PDF]

Circ Rep
Ueda N, Ishibashi K, Noda T, Oka S, Miyazaki Y, Wakamiya A, Nakajima K, Kamakura T, Wada M, Inoue Y, Miyamoto K, Nagase S, Aiba T, Kanzaki H, Izumi C, Noguchi T, Kusano K.   +16 more
europepmc   +1 more source

Optimization of novel compounds using computer‐aided drug design for treatment of cardiac arrhythmia

British Journal of Pharmacology, EarlyView.
Background and Purpose Loss‐of‐function mutations of the voltage‐gated Kv7.1 (KCNQ/KCNE1) channels lead to cardiac arrhythmia such as long QT syndrome, characterized by a prolonged QT interval . One strategy to correct the prolonged QT interval is to design molecules that activate KCNQ1/KCNE1 channels and restore the QT interval.
Jessica Jowais, Laura M. Castro‐Gonzalez, Alessia Golluscio, D. Peter Tieleman, H. Peter Larsson   +4 more
wiley   +1 more source

Protocol of the RADIO-STAR trial: a phase 1 safety and dose finding study of hypofractionated radiotherapy to the stellate ganglia for the treatment of ventricular arrhythmia. [PDF]

BMJ Open
Bussmann BM, George B, Robinson M, Grist J, Sukumar P, Chinherende E, Sheerin F, Enzhil V, Rider O, Jones B, Sabharwal A, Herring N.   +11 more
europepmc   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source